参考文献:
[1]GINS P, SOL E, ANGELI P, et al. Hepatorenal syndrome[J]. Nat Rev Dis Primers, 2018, 4(1): 23.
[2]ANGELI P, GINS P, WONG F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites[J]. J Hepatol, 2015, 62(4): 968-974.
[3]RESTUCCIA T, ORTEGA R, GUEVARA M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study[J]. J Hepatol, 2004, 40(1): 140-146.
[4]MEOLA M, NALESSO F, PETRUCCI I, et al. Clinical scenarios in acute kidney injury: Hepatorenal syndrome[J]. Contrib Nephrol, 2016, 188: 33-38.
[5]LEITHEAD JA, HAYES PC, FERGUSON JW. Review article: Advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction[J]. Aliment Pharmacol Ther, 2014, 39(7): 699-711.
[6]WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60(1): 197-209.
[7]MANDORFER M, HECKING M. The renaissance of cholemic nephropathy: A likely underestimated cause of renal dysfunction in liver disease[J]. Hepatology, 2019, 69(5): 1858-1860.
[8]GLASS L, SHARMA P. Evidence-based therapeutic options for hepatorenal syndrome[J]. Gastroenterology, 2016, 150(4): 1031-1033.
[9]KIM HY, CHO EJ, CHUN S, et al. Red blood cell alloimmunization in korean patients with myelodysplastic syndrome and liver cirrhosis[J]. Ann Lab Med, 2019, 39(2): 218-222.
[10]SANYAL AJ, BOYER T, GARCIA-TSAO G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J]. Gastroenterology, 2008, 134(5): 1360-1368.
[11]GLUUD LL, CHRISTENSEN K, CHRISTENSEN E, et al. Terlipressin for hepatorenal syndrome[J]. Cochrane Database Syst Rev, 2012, (9): CD005162.
[12]GIFFORD FJ, MORLING JR, FALLOWFIELD JA. Systematic review with meta-analysis: Vasoactive drugs for the treatment of hepatorenal syndrome type 1[J]. Aliment Pharmacol Ther, 2017, 45(5): 593-603.
[13]ISRAELSEN M, KRAG A, ALLEGRETTI AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome[J]. Cochrane Database Syst Rev, 2017, 9(9): CD011532.
[14]NGUYEN-TAT M, JGER J, REY JW, et al. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2[J]. United European Gastroenterol J, 2019, 7(4): 529-537.
[15]SINGH V, GHOSH S, SINGH B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study[J]. J Hepatol, 2012, 56(6): 1293-1298.
[16]QIN YX, LONG FL, MAO DW, et al. Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome:A Meta - analysis[J]. J Clin Hepatol, 2019, 35(10): 2266-2271.(in Chinese)
覃艳新, 龙富立, 毛德文, 等. 去甲肾上腺素或特利加压素联合白蛋白治疗1型肝肾综合征效果及安全性比较的Meta分析[J]. 临床肝胆病杂志, 2019, 35(10): 2266-2271.
[17]ZIRONI G, ROSSI C, SIRINGO S, et al. Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: A double-blind, controlled study[J]. Liver, 1996, 16(4): 225-234.
[18]CAVALLIN M, KAMATH PS, MERLI M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial[J]. Hepatology, 2015, 62(2): 567-574.
[19]WANG L, LONG Y, LI KX, et al. Pharmacological treatment of hepatorenal syndrome: A network meta-analysis[J]. Gastroenterol Rep (Oxf), 2020, 8(2): 111-118.
[20]European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J] J Hepatol, 2018, 69(2): 406-460.
[21]SRIVASTAVA S, SHALIMAR, VISHNUBHATLA S, et al. Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome[J]. J Clin Exp Hepatol, 2015, 5(4): 276-285.
[22]SCHRIER RW, GROSS P, GHEORGHIADE M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. N Engl J Med, 2006, 355(20): 2099-2112.
[23]PIAO LS. Clinical effect of tolvaptan combined with albumin in treatment of liver cirrhosis patients with type 2 hepatorenal syndrome[J]. Guide China Med, 2015, 13(25): 150. (in Chinese)
朴莲淑. 托伐普坦联合白蛋白治疗肝硬化合并2型肝肾综合征的疗效观察[J]. 中国医药指南, 2015, 13(25): 150.
[24]HIRAMINE Y, UTO H, MAWATARI S, et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites[J]. Hepatol Res, 2019, 49(7): 765-777.
[25]SNOWDON VK, LACHLAN NJ, HOY AM, et al. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial[J]. PLoS Med, 2017, 14(2): e1002248.
[26]DE BK, GANGOPADHYAY S, DUTTA D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: A randomized controlled trial[J]. World J Gastroenterol, 2009, 15(13): 1613-1619.